REPLIGEN CORP Increase Decrease In Operating Lease Liability
REPLIGEN CORP (RGEN) reported Increase Decrease In Operating Lease Liability of -$13.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-29
- REPLIGEN CORP increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$7.76M.
- REPLIGEN CORP increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$5.59M.
- REPLIGEN CORP increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$3.46M.
- REPLIGEN CORP increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$2.29M.
- REPLIGEN CORP increase decrease in operating lease liability for fiscal 2025 was -$15.56M.
- REPLIGEN CORP increase decrease in operating lease liability for fiscal 2024 was -$8.29M.
- REPLIGEN CORP increase decrease in operating lease liability for fiscal 2023 was -$12.73M.
- REPLIGEN CORP increase decrease in operating lease liability for fiscal 2022 was -$1.95M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 3 month as first filed | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 6 month as first filed | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 9 month as first filed | Increase Decrease In Operating Lease Liability 12 month | Increase Decrease In Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$13.36M 10-Q · filed 2026-07-29 | -$16.82M derived: sum of 3 quarters · filed 2026-07-29 | -$19.11M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | -$5.59M 10-Q · filed 2026-05-06 | -$9.05M derived: sum of 2 quarters · filed 2026-05-06 | -$11.35M derived: sum of 3 quarters · filed 2026-05-06 | -$16.31M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | -$3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.75M derived: sum of 2 quarters · filed 2026-02-26 | -$10.72M derived: sum of 3 quarters · filed 2026-07-29 | -$15.56M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$7.26M derived: sum of 2 quarters · filed 2026-07-29 | -$12.10M 10-Q · filed 2025-11-04 | -$14.54M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | -$4.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$9.80M 10-Q · filed 2026-07-29 | -$12.25M derived: sum of 3 quarters · filed 2026-07-29 | -$16.90M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | -$4.84M 10-Q · filed 2026-05-06 | -$7.28M derived: sum of 2 quarters · filed 2026-05-06 | -$11.93M derived: sum of 3 quarters · filed 2026-05-06 | -$11.75M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$7.09M derived: sum of 2 quarters · filed 2026-02-26 | -$6.92M derived: sum of 3 quarters · filed 2026-02-26 | -$8.29M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | -$4.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$4.47M derived: sum of 2 quarters · filed 2025-11-04 | -$5.85M 10-Q · filed 2025-11-04 | -$10.90M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.20M 10-Q · filed 2025-08-07 | $23.87M 10-Q · filed 2024-07-30 | -$6.25M derived: sum of 3 quarters · filed 2026-02-26 | -$9.38M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | -$1.38M 10-Q · filed 2025-04-29 | $22.48M 10-Q · filed 2024-05-01 | -$6.43M derived: sum of 2 quarters · filed 2026-02-26 | -$9.56M derived: sum of 3 quarters · filed 2026-02-26 | -$11.23M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$5.05M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | -$8.18M derived: sum of 2 quarters · filed 2026-02-26 | -$9.86M derived: sum of 3 quarters · filed 2026-02-26 | -$12.73M 10-K · filed 2026-02-26 | -$9.23M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | -$3.13M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$4.81M derived: sum of 2 quarters · filed 2024-11-18 | -$7.68M 10-Q/A · filed 2024-11-18 | -$8.08M derived: sum of 4 quarters · filed 2025-03-14 | ||||
| 2023-06-30 | -$1.67M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$4.54M 10-Q/A · filed 2024-11-18 | -$4.95M derived: sum of 3 quarters · filed 2025-03-14 | -$6.41M derived: sum of 4 quarters · filed 2025-03-14 | ||||
| 2023-03-31 | -$2.87M 10-Q/A · filed 2024-11-18 | -$3.27M derived: sum of 2 quarters · filed 2025-03-14 | -$4.74M derived: sum of 3 quarters · filed 2025-03-14 | -$3.69M derived: sum of 4 quarters · filed 2025-03-14 | ||||
| 2022-12-31 | -$405.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$1.87M derived: sum of 2 quarters · filed 2025-03-14 | -$817.00K derived: sum of 3 quarters · filed 2025-03-14 | -$1.95M 10-K · filed 2025-03-14 | $28.62M 10-K · filed 2023-02-22 | |||
| 2022-09-30 | -$1.46M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | -$412.00K derived: sum of 2 quarters · filed 2024-11-18 | -$1.55M 10-Q/A · filed 2024-11-18 | $26.16M 10-Q · filed 2022-11-01 | -$12.50M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-06-30 | $1.05M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | -$87.00K 10-Q/A · filed 2024-11-18 | $23.85M 10-Q · filed 2022-08-02 | -$11.04M derived: sum of 3 quarters · filed 2024-11-18 | -$4.29M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2022-03-31 | -$1.14M 10-Q/A · filed 2024-11-18 | -$17.00K 10-Q · filed 2023-05-02 | -$12.09M derived: sum of 2 quarters · filed 2024-11-18 | -$5.33M derived: sum of 3 quarters · filed 2024-11-18 | ||||
| 2021-12-31 | -$10.95M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | -$4.20M derived: sum of 2 quarters · filed 2024-11-18 | -$7.91M 10-K/A · filed 2024-11-18 | $6.96M 10-K · filed 2023-02-22 | ||||
| 2021-09-30 | $6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $3.04M 10-Q · filed 2022-11-01 | ||||||
| 2021-06-30 | -$3.71M 10-Q · filed 2022-08-02 | |||||||
| 2020-12-31 | -$1.96M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |